A statistically significant reduction from baseline in Valsalva LVOT gradient was observed with mavacamten vs placebo at week 28. Topline data were announced from a phase 3 trial evaluating mavacamten ...
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak ...
Bristol Myers Squibb (BMS) has announced positive top line results from the Phase III SCOUT-HCM trial assessing Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results